NASDAQ:DXCMDexCom Stock Price, Forecast & News

DexCom's stock was trading at $252.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DXCM stock has increased by 72.4% and is now trading at $435.11. View which stocks have been most impacted by Coronavirus.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DexCom.

DexCom is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for DexCom.

DexCom will be holding an earnings conference call on Tuesday, July 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings results on Tuesday, April, 28th. The medical device company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.29. The medical device company had revenue of $405.10 million for the quarter, compared to the consensus estimate of $358.34 million. DexCom had a return on equity of 26.44% and a net margin of 9.24%. The business's quarterly revenue was up 44.4% compared to the same quarter last year. During the same period last year, the business earned ($0.05) earnings per share. View DexCom's earnings history.

21 brokers have issued 1 year price targets for DexCom's stock. Their forecasts range from $190.00 to $500.00. On average, they anticipate DexCom's share price to reach $352.15 in the next twelve months. This suggests that the stock has a possible downside of 19.1%. View analysts' price targets for DexCom.

News articles about DXCM stock have trended negative on Thursday, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. DexCom earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned media coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about DexCom.

DexCom saw a drop in short interest in June. As of June 30th, there was short interest totaling 4,400,000 shares, a drop of 7.8% from the June 15th total of 4,770,000 shares. Based on an average daily trading volume, of 1,830,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 4.9% of the company's stock are sold short. View DexCom's Current Options Chain.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD), Steris (STE) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Netflix (NFLX), Advanced Micro Devices (AMD), salesforce.com (CRM), Vertex Pharmaceuticals (VRTX), Adobe (ADBE), ServiceNow (NOW) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.07%), State of Alaska Department of Revenue (0.02%), DNB Asset Management AS (0.01%), HNP Capital LLC (0.00%), Paragon Advisors LLC (0.00%) and Diversified Trust Co (0.00%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View institutional ownership trends for DexCom.

DXCM stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, DNB Asset Management AS, HNP Capital LLC, Paragon Advisors LLC, Diversified Trust Co, and Envestnet Asset Management Inc.. View insider buying and selling activity for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $435.11.

DexCom has a market capitalization of $40.18 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

The official website for DexCom is www.dexcom.com.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]